GMR Solutions Inc is a holding company, along with its various subsidiaries, that delivers compassionate, quality medical care, meeting a patient's unplanned and planned care needs... Show more
GMR Solutions Inc. is the nation's largest provider of emergency medical services (EMS), operating an integrated ground and air ambulance network that serves approximately 1,400 counties and reaches about 200 million Americans — roughly 60% of the U.S. population. The company responded to roughly 46 million emergencies in 2025 and operates about 50 communication centers and 24 dispatch centers, managing tens of millions of radio transmissions annually. This scale gives GMR structural advantages in dispatch efficiency, fleet utilization, and contract coverage that smaller regional operators generally cannot replicate.
The revenue base is diversified, with commercial payors at roughly 63% of the mix, Medicare at about 26%, and Medicaid near 9% — no single commercial payor accounts for more than 5% of revenue. A national ambulance contract with the Federal Emergency Management Agency (FEMA) further anchors demand during disasters. Strategically, management has outlined a target of mid-to-high single-digit organic revenue growth and high single-digit growth in earnings before interest, taxes, depreciation, and amortization (EBITDA), with a long-term EBITDA margin goal above 20%. The medium-term question is whether pricing discipline and mix improvements can outpace the cost of carrying a substantial debt load.
Several catalysts could influence investor sentiment over the coming quarters. The next earnings release — expected around November 19, 2026 — will be a focal point, with investors watching whether adjusted EBITDA holds up against softer transport volumes and whether guidance is maintained or adjusted. Continued execution on higher-margin air ambulance and air medical transport is a closely watched driver, given that recent quarters have shown net revenue per transport rising on better air mix and pricing.
Credit-market developments matter as much as operations. In May 2026 the company welcomed rating actions from Moody's Ratings and S&P Global Ratings, and future upgrades or refinancing activity could meaningfully reduce interest expense. Capital allocation decisions — including any use of free cash flow to pay down debt versus reinvest in fleet and aircraft — will be scrutinized.
On the analyst front, sentiment is positive but has cooled slightly. Major banks initiated coverage in June 2026 with a range of views: Goldman Sachs initiated with a Buy and a $35 target (later trimmed to $30), while UBS ($20), BofA Securities ($18), Citigroup ($17), Barclays ($16), and J.P. Morgan ($15, later raised to $16) all launched with constructive ratings. Morgan Stanley took a more measured stance with an Equal-weight rating and a $14 target, citing a difficult operating backdrop. The consensus price target sits near $19, well above recent trading levels, but the dispersion — from $14 to $30 — reflects genuine disagreement about execution and leverage risks.
GMR's trajectory is tightly linked to U.S. healthcare utilization, demographic aging, and the economics of out-of-hospital care. An aging population supports structurally rising demand for emergency transport, but near-term volumes have been tempered by sector-wide macro and supply-chain constraints. Labor inflation among emergency medical technicians, paramedics, nurses, and pilots is a persistent margin pressure point.
Interest rates are a direct and material variable. With a large floating and refinancing-prone debt base, higher borrowing costs compress net income, while any easing cycle would be a tailwind for deleveraging. Reimbursement policy from Medicare and Medicaid, along with commercial payor rate negotiations, remains a regulatory sensitivity that could reshape pricing power. Finally, aircraft and vehicle availability and fuel costs influence both the air ambulance business and operating expense, making the company partly commodity- and supply-chain-exposed despite its essential-service profile.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the next week or month. The platform is built to help users identify developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad universe of tradable instruments. Searchable prediction categories, historical context, and alert-oriented functionality support a more data-driven view of short-term direction. For those tracking GMR Solutions alongside the broader healthcare services sector, the Trend Prediction Engine offers a practical way to monitor shifting momentum signals as catalysts unfold.
Looking into 2026 and beyond, the central theme is whether GMR can convert its dominant market position into durable free cash flow while steadily lowering leverage. Consensus models published by sell-side analysts, including Morgan Stanley, project revenue of roughly $6.0 billion in 2026 and $6.3 billion in 2027, with adjusted EBITDA rising from about $1.15 billion to $1.24 billion. These assumptions imply modest top-line growth, gradual margin expansion, and meaningful deleveraging — all of which depend on stable pricing and disciplined cost control.
Longer-term structural drivers include an aging U.S. population, expansion into higher-acuity and air transport services, and potential market-share gains in rural and government-supported regions where GMR is often the sole integrated provider. Cost-structure evolution — particularly workforce productivity and fleet optimization — will determine whether margin targets above 20% are attainable. Competitive threats are limited by high barriers to entry, but regulatory scrutiny on billing practices and surprise-billing rules remains a persistent risk. As consensus expectations evolve, investors will likely reward visible progress on debt reduction and consistent EBITDA delivery over headline growth.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry HospitalNursingManagement
The RSI Oscillator for GMRS moved out of oversold territory on October 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 1 similar instances when the indicator left oversold territory. In 1 of the 1 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 4 of 5 cases where GMRS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +3.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMRS advanced for three days, in 11 of 15 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
GMRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GMRS as a result. In 3 of 3 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GMRS entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.686) is normal, around the industry mean (208.195). P/E Ratio (6.348) is within average values for comparable stocks, (175.456). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.502) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. GMRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.